Assets and Liabilities Measured at Fair Value (Details) $ in Thousands	3 Months Ended
Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)
Assets:
Fair value of assets	$ 345,540	$ 427,084
Liabilities:
Contingent consideration payable	20,767	19,700
Deferred compensation plan liability	3,613	2,732
Fair value of liabilities	24,380	22,432
Exchange agreement, aggregate principal amount	219,300
Milestone payment, stock issued as consideration	9,000
Common Stock
Liabilities:
Milestone payment, stock issued as consideration	(9,300)
T B200 Pompe Program \| Contingent Consideration Liability Clinical and Regulatory Milestones \| Callidus Biopharma Inc
Liabilities:
Contingent consideration payable	$ 20,538
T B200 Pompe Program \| Contingent Consideration Liability Clinical and Regulatory Milestones \| Probability of Milestone Achievement \| Minimum \| Callidus Biopharma Inc
Liabilities:
Discount rate	0.750
T B200 Pompe Program \| Contingent Consideration Liability Clinical and Regulatory Milestones \| Probability of Milestone Achievement \| Maximum \| Callidus Biopharma Inc
Liabilities:
Discount rate	0.780
Commercial paper
Assets:
Fair value of assets	$ 134,993	115,141
Asset-backed securities
Assets:
Fair value of assets	68,300	68,135
Corporate debt securities
Assets:
Fair value of assets	138,284	240,726
Money market funds
Assets:
Fair value of assets	3,963	3,082
Level 2
Assets:
Fair value of assets	345,540	427,084
Liabilities:
Contingent consideration payable	0	0
Deferred compensation plan liability	3,613	2,732
Fair value of liabilities	3,613	2,732
Convertible debt, fair value	71,600
Level 2 \| Commercial paper
Assets:
Fair value of assets	134,993	115,141
Level 2 \| Asset-backed securities
Assets:
Fair value of assets	68,300	68,135
Level 2 \| Corporate debt securities
Assets:
Fair value of assets	138,284	240,726
Level 2 \| Money market funds
Assets:
Fair value of assets	3,963	3,082
Level 3
Liabilities:
Contingent consideration payable	20,767	19,700
Deferred compensation plan liability	0	0
Fair value of liabilities	$ 20,767	$ 19,700
Level 3 \| T B200 Pompe Program \| Contingent Consideration Liability Clinical and Regulatory Milestones \| Probability Weighted Discounted Cash Flow \| Discount Rate \| Callidus Biopharma Inc
Liabilities:
Discount rate	0.103

Contingent Consideration, Measurement Input

No definition available.

Name:	fold_ContingentConsiderationMeasurementInput
Namespace Prefix:	fold_
Data Type:	xbrli:decimalItemType
Balance Type:	na
Period Type:	instant

- Definition

Debt Instrument, Convertible Debt, Exchange Agreement, Aggregate Principal Amount

+ References

No definition available.

+ Details

Name:	fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Milestone Payment, Stock Issued As Consideration

+ References

No definition available.

+ Details

Name:	fold_MilestonePaymentStockIssuedAsConsideration
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258

+ Details

Name:	us-gaap_AssetsFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- References

No definition available.

+ Details

Name:	us-gaap_AssetsFairValueDisclosureAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.

+ References

No definition available.

+ Details

Name:	us-gaap_ConvertibleDebtFairValueDisclosures
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.

+ References

No definition available.

+ Details

Name:	us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Fair value of financial and nonfinancial obligations.

+ References

+ Details

Name:	us-gaap_LiabilitiesFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- References

No definition available.

+ Details

Name:	us-gaap_LiabilitiesFairValueDisclosureAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=fold_TB200PompeProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MeasurementInputTypeAxis=fold_MeasurementInputProbabilityOfMilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: